

**2022 NYSAM Annual Virtual Meeting
February 11-12, 2022**



Source: www.everydaypower.com

***NYSAM: Moving Forward with Opportunities
Despite Challenges***

NYSAM BOARD MEMBERS

Timothy Wiegand, MD, FACMT, FAACT, DFASAM

President

timothy_wiegand@urmc.rochester.edu

Kelly S. Ramsey, MD, MPH, MA, FACP

President-Elect, Education Committee Chair, Regional Director to ASAM

kellysramsey@yahoo.com

Dorothy Lennon, MD

Secretary

dlennon@twcnny.rr.com

Ross Sullivan, MD

Treasurer

sullivar@upstate.edu

Michael Delman, MD

Immediate Past President, Nominations Committee Chair

nicedreams@verizon.net

Aaron Fox, MD

Public Policy Committee Chair

ADFOX@montefiore.org

Merrill Herman, MD

Membership Committee Chair

mherman@montefiore.org

Greg Bunt, MD

Membership Committee Co-Chair

buntmd@aol.com

Norm Wetterau, MD
Public Policy Committee Co-Chair
normwetterau@aol.com

Jade Malcho, MD
Early Career Physician
jade_malcho@urmc.rochester.edu

Eric Collins, MD
Nominations Committee Co-Chair
edc3@cumc.columbia.edu

Jun David, MD
Bylaws Committee Chair
jundavid83@aol.com

Linda Wang, MD
Education Committee Co-Chair
linda.wang2@mountsinai.org

Kristine Torres-Lockhart, MD
Communications Chair
ktorresloc@montefiore.org

Jeffrey Selzer, MD, DFASAM
NYSAM Parliamentarian
jselzer@chpny.org

NYSAM AWARDS 2022

NYSAM Lifetime Achievement Award in Addiction Medicine:

Recipient: Norman W. Wetterau, MD, FAAP, DFASAM

In grateful appreciation of your contributions to the field of Addiction Medicine, NYSAM, ASAM and the many patients who you helped live with Substance Use Disorders.

Presented on February 12, 2022, at the NYSAM Virtual 18th Annual Scientific and Treatment Conference



Norman Wetterau began treating substance use disorder (SUD) in his rural family practice in the mid-1970s and developed a passion for trying to get primary care providers not to overlook SUD in their patients. He worked as a family physician at Tricounty Family Medicine in Dansville, NY and was successful in getting his entire provider group to prescribe buprenorphine. He also worked part time at CASA Trinity, an outpatient program, which he initially helped found in the 1980s. He has a passion for prevention efforts in teens and has spoken nationally on the subject and helped write the MSSNY Youth at Risk Report.

In MSSNY (Medical Society of the State of NY), he was Chair of the Addiction Committee and successfully advocated support for syringe services programs and drug courts. He was on the NYSAFP (NYS Academy of Family Physicians) Board of

Directors and was a recurrent speaker on addiction at their annual conferences. He was NYS Family Physician of the year in 1998. He assisted in the development of the NY Chapter of ASAM (NYSAM) and served as President for 4 years. He formed the ASAM Primary Care Workgroup, served on the ASAM Board of Directors and served as Co-Chair of the Chapters Council. He represented ASAM interests to the AAFP (American Academy of Family Physicians) and PCPCC (Patient Centered Primary Care Collaborative). He helped found the Addiction Interest Group in STFM (Society of Teachers of Family Medicine). All his efforts were to encourage primary care providers to address SUD in their patients.

He is a Clinical Associate Professor of Family Medicine at the University of Rochester and teaches Family Medicine residents, mainly in his clinical practice. In 2016, he represented ISAM (International Society of Addiction Medicine) at the Special Session of the UN General Assembly on the World Drug Problem. He taught primary care psychiatry in Burundi, Africa for one month per year for 6 years. He considers his greatest accomplishment to be helping those with SUD recover.

President's Award:

Recipient: Melissa Weimer, DO, MCR, FASAM

For your outstanding contribution to The New York Society of Addiction Medicine

Presented on February 12, 2022, at the NYSAM Virtual 18th Annual Scientific and Treatment Conference



Associate Professor of Medicine (General Medicine) and of Epidemiology (Chronic Diseases); Medical Director of the Addiction Medicine Consult Service, Program in Addiction Medicine; Associate Program Director of the Addiction Medicine Fellowship Program, Medicine, Yale University

Melissa B. Weimer, DO, MCR, FASAM is an Associate Professor of Medicine and Public Health at Yale School of Medicine and Yale School of Public Health. She is a clinician-educator who is board certified in both Internal Medicine and Addiction Medicine. She is the Director of the Yale Addiction Medicine Consult Service at Yale New Haven Hospital and Associate Program Director for the Yale Addiction Medicine Fellowship program. Dr. Weimer has a clinical and research focus on improving the care of patients with addiction and its associated comorbidities, particularly in the hospital setting, and has specialty expertise in the treatment of complex pain. She is also passionate about expanding the workforce of healthcare professionals who can treat individuals with substance use disorders.

Dr. Weimer is a national leader in hospital-based addiction treatment models and expanding hospital-based addiction clinical care. She is a national leader in addiction education and has written and delivered curricula for health care professionals through the American Academy of Addiction Psychiatry Providers' Clinical Support System, the newly released American Medical Association and American Society of Addiction Medicine Buprenorphine Mini-Course, and the beloved Internal Medicine podcast called "Curbsiders". Dr. Weimer lectures nationally and regionally about addiction medicine, safe opioid use for pain, and hospital-based addiction care. She holds nationally recognized leadership positions through the American Society of Addiction Medicine including as the chairs of the Treatment of Substance Use Disorders Committee and the Clinical Practice Guidelines Methodology Committee.

Founder's Award:

Recipient: Merrill Scot Herman, MD

In recognition of your role as a founding father and President of the New York Chapter of the American Society of Addiction Medicine and your continued work on behalf of NYSAM.

Presented on February 12, 2022, at the NYSAM Virtual 18th Annual Scientific and Treatment Conference



Associate Professor, Department of Psychiatry and Behavioral Sciences, AECOM, Associate Director of Psychiatry Department of Psychiatry and Behavioral Sciences, Einstein/Montefiore Medical Center

Dr. Merrill Herman has worked in the field of substance use disorder for over 25 years. He is Chief of Service of the Montefiore Substance Abuse Treatment Program, a large opioid treatment program in the Bronx. Dr. Herman has published papers and presented at conferences on numerous subjects including acupuncture for cocaine use disorder, medical student impairment, integration of primary care and substance use disorder treatment, and co-occurring substance use disorder and psychiatric disorders.

Dr. Herman is a founding member of the Board of Directors of the Institute for Professional Development in Addictions (IPDA) in New York State. He served as the President of the New York Society of Addiction Medicine (NYSAM), a chapter of ASAM, from 1995 to 2009 and currently serves as the NYSAM Membership Committee Chair.

Dr. Herman attended University of Pennsylvania for his BA in Biology and completed medical school at Weill Cornell University Medical College,

psychiatric residency at Albert Einstein College of Medicine/Montefiore Medical Center, and the first fellowship in addiction psychiatry at New York University.

Dr. Herman's outside interests include being an avid sports fan, hiking and biking, as well as listening to popular music.

NYSAM BOD Award to the President of the NYSAM BOD:

Recipient: Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM

President, New York Society of Addiction Medicine Board of Directors, 2020 and 2021, Thank you for your service

Presented on February 12, 2022 at the NYSAM Virtual 18th Annual Scientific and Treatment Conference



Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM, specializes in Medical Toxicology and Addiction Medicine. He is an Associate Professor of Emergency Medicine and the Director of Toxicology and the Toxicology/Addiction Consult Service at Strong Memorial Hospital and the University of Rochester Medical Center. He also recently became Program Director for the URMCA Addiction Medicine Fellowship Program, based out of the Department of Emergency Medicine. Dr. Wiegand is also the Medical Director for Huther Doyle, an addiction services provider in Rochester, New York, where he works in a collaborative

model providing a variety of services for patients with substance use disorders and serves as a facilitator for their Project ECHO program on Pain, Opioid Prescribing and Addiction.

In addition to ED, hospital, and clinic work treating drug exposures, intoxication, withdrawal, and assisting with pain management for patients maintained on Medications for Opioid Use Disorder (MOUD) in the ED, hospital, and perioperative setting, Dr. Wiegand is involved with medical education and research in toxicology and addiction. He is the Program Director for the UR Emergency Medicine & Toxicology based Addiction Medicine Fellowship, and he is core faculty for the Emergency Medicine residency at Strong Memorial Hospital. In addition, he lectures locally, regionally, nationally, and internationally on addiction medicine and medical toxicology topics. Dr. Wiegand currently serves on the ASAM Board of Directors as Vice President; and is completing a second term as a board member of the American College of Medical Toxicology.

Dr. Wiegand is also the President of the New York Chapter of the American Society of Addiction Medicine (NYSAM). Dr. Wiegand is particularly interested in integrating and collaborating between addiction medicine and medical toxicology. To this end, he has Chaired and served on the Addiction Medicine Committee for ACMT and coordinated or participated in many presentations from toxicologists at the annual scientific meeting for ASAM and his state chapter, NYSAM. He is also the Moderator for the new ACMT/ASAM Addiction and Toxicology Case Conference, emphasizing the treatment of substance use disorder during the COVID-19 pandemic, which is broadcast live on the first Friday of each month from 1:00 to 2:00 EST and past webinars archived on the ASAM website.

Dr. Wiegand serves in a volunteer capacity for many local, state, and national committees, including as Medical Director for overdose prevention programs in Rochester, New York, on state advisory panels for the Department of Health and New York Aids Institute, and the New York Buprenorphine Work Group among others. He has been awarded the Charlotte Hegedus Award from the National Council on Alcoholism and Drug Dependence for professionals who have consistently demonstrated a high level of cooperative work with individuals or

groups with substance use disorders for at least five years. From ASAM, Dr. Wiegand has been awarded the Millennium Labs Late-Breaking Abstract Research Award Twice with submissions on A.) Addiction Medicine Training in Medical Toxicology Fellowship Programs and B.) The Interpretation of Buprenorphine Metabolite Levels in Urine Drug Testing. He was also the mentor and senior author to Dr. Jade Malcho, whose poster: Three Cases of Buprenorphine Micro induction in Critically Ill Patients was awarded the 2020 Virtual ASAM Conference Young Investigator Award for Best Poster. Dr. Wiegand is the 2022 awardee of the American Society of Addiction Medicine Annual Award to be presented at the ASAM Annual Conference in Hollywood, Florida, in April 2022. This award is given to an individual for outstanding contributions to the growth and vitality of ASAM, for thoughtful leadership in the field, and for a deep understanding of the art and science of Addiction Medicine.” And “for expanding the frontiers of the field of Addiction Medicine and broadening our understanding of the addictive process, through research and innovation.”

NYSAM President's Welcome

NYSAM Members and all other Conference Attendees,

First, I want to thank you for your registration and attendance at the 2022 New York Society of Addiction Medicine (NYSAM) Virtual Event. I know there are a lot of competing interests and as we move into the third year of the COVID-19 pandemic many of us have faced hardship and loss, whether personally or professionally, due to pandemic and its impact on public health, medicine, and society. While it has been a time of great tragedy and loss, with impact on our patients and a growing crisis of mental health and substance use that has still not peaked, there have been great opportunities and innovation including regulatory changes and changes in the way we deliver care that have expanded access and created new treatment models in a variety of different ways.

So, welcome to the NYSAM 2022 Annual Public Policy Day and Intersection of Science, Policy, and Treatment Conference. While last year's virtual event was a tremendous success, put together with the help of MSSNY and leadership of Dr. Kelly S. Ramsey and Dr. Aaron Fox as the first large virtual event NYSAM had done, I was really hoping this year could be in person. I miss the camaraderie and collegiality that the in-person event brings, and I know I've mentioned my penchant for New York dining (sushi, Prince Street Pizza, and Katz's Deli in particular). I look forward to when we can host the in-person event and we can each enjoy the city again whether it be for the food, entertainment, such as a Broadway show, or for many of the other attractions. But this year we have an outstanding program with experts from not only from New York but also national and even international guest speakers. The virtual conference does allow us to expand not only our speakers but also to reach a broader audience. So, if you are joining from outside of our NYSAM membership, from a partner organization or from another state we appreciate your interest and look forward to your participation in this year's conference. 2022 also marks the end of my Presidency of NYSAM, and, while the annual conference has been one of the highlights I've also been pleased to see the growth of and membership participation in our very active Public Policy Committee, the development of an ongoing webinar series on Cannabis with 3 webinars recorded for the NYSAM website and an upcoming 4th webinar series by Michael J. Kosnett, MD, MPH, FACMT from the University of Colorado School of Medicine, who will be discussing, "Assessing Workplace and Driving Impairment from Acute Use of Cannabis: Challenges and Recent Developments."

During my tenure we've also transitioned our administrative support to the Medical Society of the State of New York (MSSNY) where we've been able to leverage key partnerships and improve our strategic focus on advocacy and legislative issues. Troy Oechsner, the Executive Vice President of MSSNY, and now the Executive Director of NYSAM leading MSSNY's administrative support. I want to thank MSSNY again for assistance in conference preparation and in support for our Board and Chapter work. We've also undertaken a Bylaws overview and revision which is nearing completion and I appreciate the comments and participation of membership as this has been an important undertaking.

Finally, if you haven't recently been to our website or checked out our social media presence (e.g., Twitter @nysamconnect), I'm very pleased to say our new Communications Chair, Dr.

Kristine Torres-Lockhart has made great strides, begun by our former Communications Chair, Dr. Melissa Weimer, in greatly expanding content and overall communications impact. NYSAM is a membership organization, and the Board serves in the interest of our members. If any of you are interested in getting more involved with NYSAM, whether by participation on a committee or have interest in any of our other activities, please reach out. Our contact information is available on the NYSAM website.

Please enjoy the conference, take some time to visit our sponsors in the breakout rooms which will be available during session breaks. We have several trainee poster presentations that I am really looking forward to hearing (we had some excellent submissions this year!). We welcome students, residents, fellows, and other trainees in particular as you are the future of medicine and our specialty and our affiliated collaborations. I'm very pleased we were able to bring this event to you free of charge. And stay to the end of the conference as the last session is the Toxicology Panel, an event I'm pleased to moderate annually. This year we have some new and returning panelists and some great case-based discussion planned.

May this year bring us all good health, success, and happiness!

Sincerely,

Timothy J. Wiegand MD, FACMT, FAACCT, DFASAM

President, NYSAM

2022 NYSAM Annual Virtual Meeting

February 11-12, 2022.

Schedule

Friday, February 11th, 1 pm – 5 pm

The Annual Public Policy Day

Scheduled topics include: Overdose Prevention Centers, Updating Methadone Regulations, Legislative Updates, and New ASAM Policy Statements

Saturday, February 12th, 8 am – 2:30 pm

The Annual Scientific and Treatment Conference

Scheduled topics include: Clinical Case Presentations; History of Office-based Methadone Maintenance in NYS; Panel Discussion on Outcomes Data for Buprenorphine Prescribing via Telemedicine; Panel on Buprenorphine Microdosing Strategies to Avoid Precipitated OWS (opioid withdrawal syndrome) in the Era of Fentanyl and Fentanyl Analogues; Toxicology Panel

Annual Policy Day Agenda

Friday, February 11th

1:00 pm-1:05 pm (5 minutes)

Welcome

Aaron D. Fox, MD MS, Associate Professor, Department of Medicine, Albert Einstein College of Medicine-Montefiore Medical Center

1:05 pm – 2:05 pm (60 minutes)

Session 1: “Addiction treatment in New York State in 2022”

Learning Objectives:

1. Learners will list at least 3 changes to New York State law that passed in 2021
2. Learners will describe at least 1 priority for OASAS in 2022

3. Learners will describe at least 1 policy change that could reduce overdose deaths

Speakers:

Senator Gustavo Rivera, New York State's 33rd Senate District, Chairman of Committee on Health

Chinazo O. Cunningham, MD MS, Commissioner, New York State Office of Addiction Services and Supports (OASAS)

Lisa Skill, MS MCHES, Office of Drug User Health, New York State Department of Health-AIDS Institute

Narelle Ellendon, RN, Office of Drug User Health, New York State Department of Health-AIDS Institute

2:05 pm – 2:15 pm (10 minutes)

Break or Visit Our Sponsors in the Breakout Rooms

2:15 pm – 3:30 pm (75 minutes)

Session 2: “Overdose Prevention Centers – current challenges and opportunities”

Learning Objectives:

1. Learners will describe the services provided at overdose prevention centers
2. Learners will describe at least one study that has examined the impact of overdose prevention centers on health outcomes
3. Learners will propose at least one initiative in which addiction medicine specialists could collaborate with overdose prevention centers

Speakers:

Sam Rivera, Executive Director, On Point NYC (New York Harm Reduction Educators and Washington Heights CORNER Project)

Brandon Marshall, PhD, Associate Professor, Department of Epidemiology, Brown University School of Public Health

Aaron D. Fox, MD MS, Associate Professor, Department of Medicine, Albert Einstein College of Medicine-Montefiore Medical Center

3:30 pm – 3:45 pm (15 minutes)

Break or Visit Our Sponsors in the Breakout Rooms

3:45 pm – 5:00 pm (75 minutes)

Session 3: “Increasing Access to Methadone Treatment”

Learning Objectives:

1. Learners will describe the regulatory framework for methadone treatment
2. Learners will describe the impact of methadone regulatory changes during the COVID-19 pandemic
3. Learners will propose at least one alternative model to current opioid treatment programs that could provide methadone treatment

Speakers:

Paul Joudrey, MD MS, Assistant Professor, General Internal Medicine, Yale School of Medicine

Shadi Nahvi, MD MS, Associate Professor of Medicine, Department of Medicine, Albert Einstein College of Medicine-Montefiore Medical Center

David Frank, PhD, Postdoctoral Fellow, Rory Meyers College of Nursing, New York University

Celyn Sai Lynn Ng, MPharm, MPH, New York State Office of Addiction Services and Supports

Annual Scientific and Treatment Conference Agenda
Saturday, February 12th

8:00 am-9:00 am (60 minutes)

Session 1: “Interesting Addiction Medicine Cases”

Learning Objectives:

1. Learners will describe the presentation and treatment of a “Fast In—Fast Out” drug
2. Learners will describe when is it safe to start IM Depot Naltrexone: the Toxicology Dilemma
3. Learners will describe of the limitations of urine toxicology
- 4.

Speaker:

Edwin A. Salsitz, MD, DFASAM, Associate Clinical Professor of Psychiatry at the Mount Sinai School of Medicine

9:00 am-9:10 am (10 minutes)

Welcome: Tim Wiegand, NYSAM President, MD, FACMT, FAACT, DFASAM and Kelly S. Ramsey, NYSAM President-elect, MD, MPH, MA, FACP, DFASAM

9:10 am-10:00 (50 minutes), Lecture by the 2021 Recipient of the NYSAM Life Achievement Award

Session 2: “History of Office-based Methadone Maintenance in NYS”

Learning Objectives:

1. Learners will describe the History and Evolution of OUD Treatment
2. Learners will describe the Intended and Unintended Consequences of the Methadone Clinic System
3. Learners will describe Methadone Medical Maintenance: An Office Based Treatment Paradigm

4. Learners will describe the Current State of Methadone OBOT (Office-based Opioid Treatment)

Speaker:

Edwin A. Salsitz, MD, DFASAM, Associate Clinical Professor of Psychiatry at the Mount Sinai School of Medicine

10:00 am-10:15 am (15 minutes)

Break or Visit Our Sponsors in the Breakout Rooms

10:15 am-11:15 am (60 minutes)

Session 3: “Panel Discussion on Outcomes Data for Buprenorphine Prescribing Via Telemedicine”

Panelist #1:

Title: “Using Telemedicine to Continue Buprenorphine Prescribing in Primary Care”

Learning Objectives:

1. Learners will describe how a New York City primary care-based buprenorphine treatment program transitioned to telemedicine during the COVID-19 pandemic
2. Learners will describe strategies for implementing telemedicine-based buprenorphine prescribing in primary care
3. Learners will describe outcomes for buprenorphine prescribing using telemedicine in primary care

Speaker:

Eric C. Woods, MD, Instructor, Department of Medicine, Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai

Panelist #2:

Title: “Panel on Outcomes Data on Buprenorphine Prescribing via Telemedicine”

Learning Objectives:

1. Learners will gain a better understanding of why Telehealth is an effective tool in treating people with OUD (opioid use disorder)
2. Learners will gain an understanding of how Telehealth can affect a region in which access to care may not be available
3. Learners will gain an understanding of the demographics of who might benefit from telephonic (audio only) care over video care
- 4.

Speaker:

Justine L. Waldman, MD, FACEP, CEO/Founder, Reach Medical, Ithaca, NY

Panelist #3:

Title: “Virtual Buprenorphine Care: A low threshold virtual buprenorphine clinic”

Learning Objectives:

1. Learners will describe how telemedicine expands access to care
2. Learners will describe how to maintain a safe low threshold, harm reduction virtual clinic
3. Learners will describe how to make a warm virtual hand off and follow up

Speaker:

Daniel Schatz, MD, MSc, Adjunct Assistant Professor of Population Health at NYU,
Director of Program and Policy at the Office of Behavioral Health,
Health + Hospitals

11:15 am-12:30 pm (75 minutes)

Session 4: “Panel on Buprenorphine Microdosing Strategies to Avoid Precipitated OWS (opioid withdrawal syndrome) in the Era of Fentanyl and Fentanyl Analogues”

Panelist #1:

Title: “Low Dose Initiation of Buprenorphine: What, Why, and How”

Learning Objectives:

1. Learners will describe clinical scenarios in which classic buprenorphine initiation is difficult or not feasible
2. Learners will describe the mechanism of low dose initiation of buprenorphine using an analogy
3. Learners will describe the principles of low dose initiation

Speaker:

Shawn Matthew Cohen, MD, Addiction Medicine Fellow, Yale University, Fellow, National Clinical Scholars Program, Yale University

Panelists #2/3/4:

Title: “Low-dose buprenorphine initiation: Rationale and the current evidence-base” and “Micro-induction, an Evolving Approach to Treating Opioid Addiction, context, challenges, and necessity”

Learning Objectives:

1. Learners will describe the rationale for low-dose buprenorphine initiation
2. Learners will describe the approaches to low-dose initiation among hospital inpatients
3. Learners will describe the approaches to low-dose initiation in the outpatient setting

Saeed Ahmed, MD, Medical Director, West Ridge Center, RPMC VT

Joji Suzuki, MD, Assistant Professor of Psychiatry, Harvard Medical School, Site Director, Boston Children's Hospital Addiction Medicine Fellowship

Ashish Prakash Thakrar, MD, Fellow, National Clinical Scholars Program, University of Pennsylvania

12:30 pm-12:45 pm (15 minutes)

Break or Visit Our Sponsors in the Breakout Rooms

OR

12:30-12:40 pm Breakout Room (10 minutes)

NYSAM Medical Student, Resident, Addiction Medicine/Addiction Psychiatry Fellow Poster Competition: Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM, Tim Wiegand, MD, FACMT, FAACT, DFASAM, and Norm Wetterau, MD

Winning Poster Presentations:

Honorable Mention:

Title: "Can Patients Enroll in Opioid Treatment Programs During Medical Hospitalization?"

Learning Objectives:

1. Learners will describe challenges in methadone clinic enrollment for the hospitalized patient and define systemic factors that contribute to these challenges
2. Learners will describe at least one strategy to improve access to methadone treatment for medically complex and hospitalized patients

Presenter: Katherine Mullins, MD, Addiction Medicine Fellow, Montefiore Medical Center

12:45 pm-1:00 pm (15 minutes)

NYSAM Awards Presentation: Tim Wiegand, MD, FACMT, FAACT, DFASAM, and Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM

1:00 pm-1:20 pm (20 minutes)

NYSAM Medical Student, Resident, Addiction Medicine/Addiction Psychiatry Fellow Poster Competition Winner Presentations: Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM, Tim Wiegand, MD, FACMT, FAACT, DFASAM, and Norm Wetterau, MD

Winning Poster Presentations:

Third Place Winner:

Title: “Improving SUD Treatment at SUNY Upstate”

Learning Objectives:

1. Learners will describe the impact of SUD on Onondaga County using various health outcome measures such as patient admissions, EMS dispatches, and overdose deaths
2. Learners will discuss the different approaches employed by institutions to improve SUD treatment
3. Learners will describe how advocates at Upstate University Hospital are implementing new methods and practices to improve SUD treatment
4. Learners will describe how current medical students are involved with SUD treatment improvement and plans to expand this program in the future

Presenters: Emma Frawley, MS3, Feng Hsiao, MS3, Anthony Corsi, MS3, and Jin Jin Ma, MS3, SUNY Upstate

Second Place Winner:

Title: “Nipping it in the bud: A pre-clinical curriculum to reduce stigma associated with substance use disorders”

Learning Objectives:

1. Learners will describe disparities in substance use disorder (SUD) treatment within the stigma framework
2. Learners will describe the role that healthcare providers play in perpetuating stigma towards individuals with SUDs
3. Learners will describe how a clinical pre-clinical curriculum in medical education can be designed to reduce stigma associated with SUDs

Presenters: Emma Brezel, MS2, and Kaitlyn Clausell, MS2, AECOM

First Place Winner:

Title: “Medical Student-Run Inpatient Naloxone Training and Distribution at Mount Sinai Hospital”

Learning Objectives:

1. Learners will describe the role of naloxone in preventing deaths due to opioid overdose.
2. Learners will describe an example of a potential workflow for inpatient naloxone training.
3. Learners will describe the feasibility of a medical-student run inpatient naloxone training and distribution program.
4. Learners will describe the future directions and challenges associated with the training protocol.

Presenters: Calla Khilnani, MS2, Nathaniel Saffran, MS2, and Zerubabbel Asfaw, MS2 Icahn SOM at Mount Sinai

1:20 pm-2:20 pm (60 minutes)

Session 5: “The NYSAM Toxicology Panel: The 2022 Update on Synthetic Drugs”

An illustrative synthetic cannabinoid case

“Pressed Xanax” and the state of the novel benzodiazepine market

Evolution of the Novel Synthetic Opioid (NSO) market and the emergency of the ‘-nitazenes’

Learning Objectives:

1. Learners will describe current trends in novel psychoactive substances in the United State related to designer benzodiazepines
2. Learners will describe synthetic cannabinoid intoxication and withdrawal
3. Learners will describe how the use of social media search technologies can help determine emerging drug use patterns and threats.
4. Learners will describe the basic pharmacology of the benzimidazole derived opioids and their emergency on the illicit drug market (e.g., isotonitazene, etonitazene, metonitazene).

Speakers:

Moderator:

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM, Moderator

President-New York Society of Addiction Medicine & Director of Addiction Toxicology and the Toxicology Consult Service, Associate Professor of Emergency Medicine at the University of Rochester Medical Center, Rochester, New York

Panelists:

Jeffrey Brent, MD, PhD, Distinguished Clinical Professor of Medicine and Emergency Medicine, University of Colorado School of Medicine and the Colorado School of Public Health, Denver, CO

Barry K Logan, PhD, FABFT, Executive Director, Center for Forensic Science Research and Education; Chief Scientist, NChMS Labs, Willow Grove, PA

Alaina Steck, MD, Assistant Professor of Emergency Medicine at Grady Memorial Hospital and the Medical Director of the Grady Medication-Assisted Opioid Treatment (MAOT) Clinic, Atlanta, GA

Stephanie Weiss, MD, PhD, Medically Accountable Investigator, Translational Addiction Medicine Branch, National Institute on Drug Abuse, National Institutes of Health

Paul Wax, MD, FACMT, Executive Director of the American College of Medical Toxicology (ACMT), Phoenix, AZ

2:20 pm-2:30 pm (10 minutes)

Closing: Tim Wiegand, NYSAM President, MD, FACMT, FAACT, DFASAM and Kelly S. Ramsey, NYSAM President-elect, MD, MPH, MA, FACP, DFASAM

This activity has been approved for **8.75 AMA PRA Category 1 Credit(s)[™]**.

AMA Credit Designation Statement:

The American Society of Addiction Medicine designates this live activity for a maximum of **8.75 AMA PRA Category 1 Credit (s)[™]**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The American Society of Addiction Medicine (ASAM) and the New York Society of Addiction Medicine. The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CME Committee Reviewer Disclosure Information:

Subhadeep Barman, MD, FAPA, FASAM – No relevant financial disclosures

NYSAM Annual Conference Speaker BIOS in order of presentation:

Public Policy Day: Friday, February 11, 2022:

Gustavo Rivera, NYS Senator, Health Committee Chair, Joint Task Force on Opioids, Addiction, and Overdose Prevention Co-Chair



State Senator Gustavo Rivera represents the 33rd Senate District in the Bronx, which includes the neighborhoods of Kingsbridge Heights, Belmont, Fordham, University Heights, Van Nest, East Tremont, Crotona and Mount Hope.

Since taking office, Senator Rivera has focused his efforts on addressing issues of health inequity both legislatively and on the ground.

In 2018, his passion to improve the health of New Yorkers led Majority Leader Andrea Stewart-Cousins to appoint Senator Rivera as the Chair of the New York State Senate's Health Committee. As the Chair, Senator Rivera's goal is to collaborate with his colleagues, stakeholders, and constituents to improve health outcomes, increase access to health coverage, and ensure a financially viable system for the 20 million New Yorkers he proudly serves.

Prior to his appointment as Chair, Senator Rivera served as the ranking member of the Senate Health Committee for six years. As a sitting member of the committee, Senator Rivera passed three laws to ban smoking around schools, after schools, and libraries, and has been a champion of public health and harm reduction policies.

In March 2017, he became the main sponsor of the “New York Health Act,” an innovative bill to create a single payer health system in New York State. In 2011, Senator Rivera launched the Bronx CAN (Changing Attitudes Now) Health Initiative. The goal of this community-oriented health initiative is not only to encourage Bronx residents to develop healthy behaviors, but to shape policies that will help tear down some of the institutional barriers that stand in the way of Bronxites having a healthier lifestyle.

Senator Rivera also worked as a community organizer on New York State campaigns, as well as on President Barack Obama’s 2008 campaign. He has worked as a college professor and briefly was a staff member for U.S. Senator Kirsten Gillibrand.

Chinazo O. Cunningham, MD, MS, Commissioner, NYS Office of Addiction Services and Supports



Dr. Cunningham is a physician, researcher, and public health professional who brings over 20 years of expertise in substance use treatment to OASAS. Prior to joining OASAS, she served as the Executive Deputy Commissioner of Mental Hygiene at the New York City Department of Health and Mental Hygiene, was a practicing physician at Montefiore Health System, and a Professor of Medicine, Family and Social Medicine, and Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine. Dr. Cunningham has more than 20 years' experience

in research, care, and program-development that focuses on people who use drugs. She has also partnered with community-based organizations to develop pioneering programs to promote the health of this population. Dr. Cunningham led one of the first clinics in New York City to integrate buprenorphine into primary care. She has trained hundreds of doctors to treat substance use disorders in primary care. She has also led several research studies and published numerous research articles that focus on treating substance use disorders.

Lisa Skill, MS, MCHES



Health Program Coordinator, Provider Education and Buprenorphine Access Initiative, New York State Department of Health, AIDS Institute, Office of Drug User Health

Lisa Skill is Health Program Coordinator at the NYS DOH AIDS Institute, Office of Drug User Health working on the Provider Education and Buprenorphine Access Initiative.

She coordinates all provider education activities to increase clinicians' capacity to prescribe buprenorphine in a variety of settings, including primary care, emergency departments, corrections and harm reduction settings. Prior to her work at the NYSDOH she provided statewide training to health and human service providers on working with People Who Use Drugs, Harm Reduction, HIV and Hepatitis. She also did community coordination work for the NYS Office for the

Prevention of Domestic Violence and worked as a Harm Reduction Specialist providing harm reduction services and interventions with PWUDs.

She served as the co-chair for the National Public Health Training Center Network and as a member of the NYS DOH HIV Prevention Planning Group.

Ms. Skill holds a Master's degree in Community Health Education and is a Master Certified Health Education Specialist

Narelle Ellendon, RN



Narelle Ellendon is a Registered Nurse and an Opioid Program Manager with the New York State Department of Health's, (NYSDOH), Office of Drug User Health. Ms. Ellendon is the lead in coordinating the expansion of buprenorphine access and other opioid overdose prevention interventions across the state. Prior to working for the NYSDOH, she was the Director of Capacity Building Services for Harm Reduction Coalition, (HRC) overseeing their national training and capacity building services to support the integration and expansion of drug user health interventions, including syringe access services, overdose prevention services, Hepatitis C and HIV prevention, screening, care and treatment. Before immigrating to the US nearly 20 years ago, Ms. Ellendon worked in Australia as an outreach community health nurse with the homeless, drug-using populations and as a registered nurse within correctional facilities, drug treatment and other healthcare settings.

Sam Rivera



Sam Rivera has over 29 years of progressive experience in social services. His primary focus of expertise lies in Criminal Justice/Reentry, HIV/AIDS, Harm Reduction, Addiction/Recovery, and Mental Health. He currently serves as the Executive Director of New York Harm Reduction Educators and Washington Heights Corner Project, two merging harm reduction organizations that provide services to active drug users and sex workers in Northern Manhattan and The South Bronx, many of whom are low-income or homeless as well as of color and LGBTQ. He brings to this role his several decades of cutting-edge service provision experience and a commitment to social justice. He has dedicated his professional career to ameliorating the harms associated with the War on Drugs, racism/sexism, structural inequality, and mass incarceration and will continue to work to end systemic as well as systematic barriers to populations that are most vulnerable.

Brandon DL Marshall, PhD



Dr. Marshall is an Associate Professor of Epidemiology at the Brown University School of Public Health. He is also founding director of the People, Place & Health Collective at Brown University. He received a PhD in epidemiology from the School of Population and Public Health at the University of British Columbia. In 2011, he completed postdoctoral training at the Columbia University Mailman School of Public Health.

Dr. Marshall focuses on substance use epidemiology, with a specific emphasis on harm reduction research and overdose prevention. His team evaluates programs and policies that aim to improve the health and well-being of people who use drugs. He has published more than 275 scientific publications and three book chapters. He has received numerous awards for his work, including the 2016 Early Career Award from the Society for Epidemiologic Research, and the 2019 Early Career Public Health Research Award from the Association of Schools & Programs of Public Health.

He has served on numerous task forces to address the nation's overdose crisis and is an *ad hoc* member of the FDA drug safety and risk management advisory committee. Dr. Marshall also serves as an expert advisor to the Rhode Island Governor's Overdose Prevention & Intervention Task Force.

Aaron Fox, MD, MS



Dr. Fox is an Associate Professor of Medicine in the Division of General Internal Medicine at Albert Einstein College of Medicine/Montefiore Medical Center. He is board certified in Internal Medicine and Addiction Medicine and has provided primary care at a community health center in the South Bronx since 2004. Dr. Fox

also studies opioid use disorder and the overlapping problems of HIV, criminal justice involvement, and chronic pain. Dr. Fox is the Director of the Bronx Transitions Clinic, which provides a medical home to formerly incarcerated individuals with chronic health conditions. He also develops and studies clinical programs that improve access to and effectiveness of buprenorphine treatment for opioid use disorder. These studies have examined peer navigation, buprenorphine group medical visits, low-threshold buprenorphine treatment at syringe services programs, and low-dose buprenorphine induction strategies.

Dr. Fox graduated from the Albert Einstein College of Medicine, trained at Montefiore's Primary Care/Social Internal Medicine Residency Program, and he received a Masters in Clinical Research from Einstein in 2012. In addition to providing clinical care and research, Dr. Fox also spent 10 years teaching a medical student elective, "Research Based Health Activism," and joined New York Society of Addiction Medicine's Board of Directors in 2020.

Paul Joudrey, MD, MPH



Dr. Joudrey is an Assistant Professor in the Yale School of Medicine and a Yale Drug use, Addiction, and HIV Research (DAHRS) Scholar. Dr. Joudrey is committed to improving the health of people with substance use disorders by expanding access to high quality evidence-based care. This includes research aiming for greater equity in access to medications for opioid use disorder, particularly methadone in rural communities, as well as improving the adoption of medications for alcohol use disorder within hospital settings. He utilizes

geospatial and implementation science methods to inform novel strategies for expanding access to these underutilized addiction treatments. Certified as a general internist and addiction medicine specialist, he serves as an attending physician within the Yale New Haven Hospital Primary Care Clinic, as well as attending physician for the Ledge Light Health District and Alliance for Living Coordinated, Access, Resources, Engagement, and Support (CARES) program which provides low barrier buprenorphine in New London County. He received his undergraduate degree from Case Western Reserve University and his medical degree from New York University. Dr. Joudrey completed residency training at Montefiore Medical Center in the Primary Care Social Internal Medicine program and completed the National Clinician Scholars Program fellowship at Yale School of Medicine

Shadi Nahvi, MD, MS



Dr. Shadi Nahvi is an Associate Professor in the Departments of Medicine and Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine, and Co-Director of the General Internal Medicine and Addiction Medicine Fellowship Programs. Her research focuses on optimizing quality of life and health outcomes among persons with substance use disorder.

Dr. Nahvi's research is grounded in over a decade of clinical experience as a primary care physician caring for persons with opioid and other substance use disorders. Her primary research focus is optimizing the efficacy and delivery of tobacco cessation treatments among persons with co-occurring substance use disorders. Currently, she is Principal Investigator of a NIDA R01-funded

randomized, 2 x 2 factorial trial of directly observed and long-term varenicline treatment among smokers with opioid use disorder. She has led studies of health system-level interventions to increase treatment of tobacco use disorder and randomized trials of the efficacy of varenicline provided at methadone clinics.

Dr. Nahvi graduated from the Brown University School of Medicine in 2001 and completed residency training in Primary Care Internal Medicine at Bellevue Hospital and New York University Medical Center in 2004. She then joined the faculty in the Albert Einstein College of Medicine Division of Substance Abuse as the Medical Director of a substance abuse treatment clinic. From 2006-2008, Dr. Nahvi completed a faculty fellowship supported by the Bronx Center to Reduce and Eliminate Ethnic and Racial Health Disparities, a NIH-funded health disparities Center of Excellence. Through this fellowship, she completed the Einstein Clinical Research Training Program and received a MS in Clinical Research Methods.

Dr. Nahvi has served on numerous national advisory committees, including serving as a member of the Advisory Committee of the Society for Research on Nicotine and Tobacco Health Disparities Network; a member of the NY State Department of Health AIDS Institute's Guideline Committee for the Care of Substance Users; and a Steering Committee member of the NY State Department of Health AIDS Institute's Tobacco Cessation Improvement Campaign.

David Frank, PhD



David Frank is a Medical Sociologist at New York University's Center for Drug Use and HIV/HCV Research. He is also a person who uses drugs and who has been on

methadone maintenance treatment for more than 15 years. Dr. Frank's work focuses on opioid use, opioid use treatment programs like medication assisted treatment (MAT), and the structural and legal context that opioid use and treatment occur within. His work specifically examines the role of structural forces, like criminalization and the War on Drugs, in the behaviors, decisions, and outcomes of people who use illegal drugs. Dr. Frank has strong ties to harm reduction and drug-user advocacy groups and uses those relationships to produce research that is both ethically-conducted and grounded in the real-world experiences of the populations he studies. He is committed to using his position as a scholar to help end the War on Drugs.

Celyn Ng, MPharm, MPH



Celyn Ng, MPharm, MPH is a Project Manager at the Bureau of Adult Treatment Services, NYS Office of Addiction Services and Supports. Prior to working in NY, Celyn was a community pharmacist in the UK providing various services including Medication-Assisted Treatment and needle exchange services within pharmacies. Recently, she managed the NYC Medication Delivery System in conjunction with the NYC Department of Health and Mental Hygiene, and the Coalition of Medication-Assisted Treatment Providers and Advocates, with the goal of ensuring patients continue to have access to methadone treatment while in isolation or quarantine due to COVID-19.

Celyn graduated from the School of Pharmacy at the University of Nottingham, UK, and the School of Global Public Health at the New York University.

Scientific and Treatment Conference: Saturday, February 12, 2022:

Edwin A. Salsitz, MD, DFASAM



Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel, Division of Addiction Medicine, New York City, since 1983, and is an Associate Clinical Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified in Addiction Medicine by the American Board of Preventive Medicine, as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.

Dr. Salsitz is a course director for ASAM sponsored Buprenorphine and REMS safe opioid prescribing trainings and is a lead mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee.

Dr Salsitz teaches addiction medicine at the Icahn School of Medicine at Mount Sinai, to third year medical students, Master of Science Students, neuroscience

Ph. D candidates, and psychiatry residents. He is a frequent contributor and presenter at the Addiction Club, led by Dr. Hurd.

Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

Dr. Salsitz is the recipient of the 2021 NYSAM Lifetime Achievement Award.

Eric Woods, MD



Dr. Woods did his medical school training at the Icahn School of Medicine at Mount Sinai, completed residency at Montefiore's Primary Care and Social Internal Medicine Program, and is now a Clinical Instructor at Mount Sinai where he spends his time teaching residents and seeing patients with substance use disorders at the REACH clinic.

Justine Waldman, MD



Justine Waldman is Board Certified in Addiction Medicine, Emergency Medicine, and a Fellow of the American College of Emergency Physicians. Since December of 2016, she has been providing Low Threshold Medications for Addiction Treatment (MAT), Hepatitis C treatment and acute care to People Who Use Drugs at the Syringe Service Program (SSP) at the Southern Tier Aids Program in Ithaca, NY. She is currently the CEO and CMO of Reach (Respectful, Equitable Access to Compassionate Health) Medical in Ithaca, NY which opened in February of 2018. REACH houses a medical practice offering integrated primary care and low threshold harm reduction services for people who tend to face stigma in the current medical system. Reach Medical offers primary care, MAT, viral screening, vaccination and treatment and on demand behavioral health care. Since the Spring of 2020, REACH has been growing a robust outreach program staffed by individuals with lived experience who offer viral screening, vaccination and treatment, acute primary care and MAT visits via telehealth. In addition, REACH is the administrative home for case management for the Ithaca Law Enforcement Assisted Diversion Program (LEAD).

REACH has an established Peer Advisory Board in which peers are provided stipends through a local foundation grant to advise REACH on various aspects of our organization, e.g., service delivery, and research. REACH has an increasingly renowned Research Department steeped in bringing the REACH model to scale (PEW grant) and studying the outcomes that are being achieved in a rural health equity setting (HRSA grants).

Daniel Schatz, MD



I am passionate about serving vulnerable patients experiencing addiction issues. Many of these individuals have experienced a life filled with trauma, violence, oppression, and now stigma that prevents them from receiving life-saving treatment that can drastically improve their quality of life. I am dedicated to identifying and addressing barriers to their care, implementing evidence-based harm reduction policies and programs, treating the entirety of the person, and educating healthcare professionals and the community about addiction.

In my current role as the Director of Program and Policy in the Office of Behavioral Health at NYC's Health + Hospitals I provide clinical oversight of our addiction initiatives throughout our system from the emergency department, to inpatient care, to outpatient behavioral health and primary care, as well as at OASAS certified clinics. Initiatives in the emergency department include oversight of our emergency department SBIRT teams, development of a new policy and procedure regarding the initiation of buprenorphine, implementation of the MATTERS (Medication Assisted Treatment and Emergency Referrals) Network platform, and development of a new policy and procedure regarding the initiation of buprenorphine, as well as development of numerous tools and resources to improve care. On the inpatient side, I provide clinical oversight to our addiction consultation services. I developed and implemented a system wide transition to a symptom triggered alcohol withdrawal protocol. I also oversaw several optimizations including methadone and buprenorphine inpatient orders, policies and procedures at our hospitals. In the outpatient setting I helped start up several primary care addiction sites, improved screening workflows and referrals through e-consult, and brought onto formulary a digital pharmaceutical therapeutic for contingency management and cognitive behavioral therapy. I also developed an innovative virtual buprenorphine clinic rapidly during the pandemic, in addition to starting several ancillary withdrawal clinics. System wide I have given dozens of grand round lectures, numerous departmental talks, led multiple addiction focused ECHO (Extension in Community Healthcare Outcomes) curriculums, and am the first contact for any addiction related clinical issue. I also helped our system develop reports, registries, and the integration of a cascade of care model for opioid use and treatment.

In addition to my administrative role, I continue to provide twenty percent clinical time in two separate primary care buprenorphine teaching clinics. I continue to

be passionate about research around topics of addiction education, opioid and alcohol use and treatment, e-cigarette use, and telemedicine.

Working in a large multi-site system, I have learned to garner consensus by starting with the evidence, empowering a panel of experts and leaders throughout the system, and getting approval of councils and executive leadership. I have learned to effectively communicate between a variety of clinical and administrative positions from peer specialists to MDs, from individual clinics to executive meetings, and from the emergency department to specialty clinics and everything in between. I am committed to using all of my skills to improve and more equitably provide health care for all people suffering from addiction.

Shawn Matthew Cohen, MD



Shawn Cohen MD is a general internist and 2nd year addiction medicine fellow. As a resident and hospitalist at a public hospital in Seattle, he saw the impact of person-centered care on people who use drugs, leading him back to an addiction medicine fellowship. His interests are in improving hospital care for people with substance use disorder, low dose initiation of buprenorphine, and low barrier outpatient care.

Saeed Ahmed, MD



Saeed Ahmed, MD, is a board-certified Psychiatrist with specialization in addiction psychiatry. After graduating from Sindh Medical College in Karachi, Pakistan, he did an Adult Psychiatry residency at Nassau University Medical Center, New York, followed by a fellowship in Addiction Psychiatry at Boston University Medical Center/VA Boston Healthcare System.


During his residency, Dr. Ahmed served as a Chief Resident as well as on various committees of the residency program. He has been actively involved with the American Psychiatric Association (APA) in various capacities including APA diversity leadership fellow and a fellow member at the APA Council on Addiction Psychiatry. He is on the American Academy of Addiction Psychiatry's membership committee as well (AAAP). He has served on committees for national and international psychiatry conferences and is currently a member of the editorial board of numerous peer-reviewed journals.

Being a former AADPRT Nyapati Rao/Francis Lu International Medical Graduate (IMG) Fellow, Dr. Ahmed has a distinct interest in mentoring IMGs, who seek residency/fellowship training in the United States.

He is now the Medical Director of the West Ridge Center at Rutland Regional Medical Center in Rutland, Vermont. He currently provides addiction treatment services at West Ridge Recover as well as on the inpatient psychiatry unit for those with and without co-occurring disorders.

Along with his clinical work, he is a widely published author with over four dozen of peer review papers. His research interests include substance use disorders, specifically, micro-induction of Buprenorphine / Naloxone, investigating off-label medications “repurposing” in substance use disorders, increasing access to and reducing barriers to the utilization of available treatments for substance use disorders.

Joji Suzuki, MD



Dr Suzuki is the Director of the Division of Addiction Psychiatry in the Department of Psychiatry, Brigham and Women’s Hospital (BWH), and an Assistant Professor of Psychiatry at Harvard Medical School (HMS). He has been a consultation-liaison psychiatrist in the Division of Medical Psychiatry at BWH, and currently serves as the Director for the BWH Bridge Clinic as well as the Program Director for the BWH Addiction Medicine Fellowship. He has been very active in both medical student and resident education throughout his career. He is a member of Motivational Interviewing Network of Trainers and is the course director for the HMS CME course on motivational interviewing. His research has received funding from National Institute on Drug Abuse (NIDA), CDC, SAMHSA, BWH, and HMS. In 2018 he was awarded a NIDA K23 Career Development Award to receive mentored training in conducting clinical trials, and to study the impact of recovery coaches on hospitalized patients with opioid use disorder. He is a sought-out speaker both locally and nationally, and currently serves on a variety of committees, workgroups, and taskforces for Mass General Brigham, HMS,

American Academy of Addiction Psychiatry, Academy of Consultation Liaison Psychiatry, and the State of Massachusetts.

Ashish Thakrar, MD



Dr. Ashish Thakrar is a fellow in the National Clinician Scholars Program at the University of Pennsylvania. He completed internal medicine residency at Johns Hopkins Hospital's Osler Training Program as part of the Urban Health-Primary Care track and Addiction Medicine fellowship at Johns Hopkins Bayview. His research and advocacy focus on increasing access to treatment for opioid use disorder in the fentanyl era and on improving care for hospitalized patients with addiction.

Katherine Mullins, MD



After graduating from Wesleyan University, Katherine spent two years studying obesity and completing an Academy Certificate in Health Disparities at the NIH. She graduated from Georgetown University School of Medicine with distinction as a Population Health Scholar. She completed her residency in the Primary Care and Social Internal Medicine Track at Montefiore in 2021, where she is currently training as an Addiction Medicine fellow. She hopes to improve access to healthcare for people who use drugs by integrating harm reduction and health justice frameworks into physician education and clinical program development.

Emma Frawley, MS3, SUNY Upstate



Emma Frawley is currently a third-year medical student at SUNY Upstate Medical University who is pursuing a career in Emergency Medicine with interests in addiction medicine and SUD treatment. She is originally from Massapequa, NY and received her undergraduate degree from Cornell University majoring in Human Biology, Health and Society with a minor in Human Development.

Feng Hsiao, MS3, SUNY Upstate



Feng Hsiao is currently a third-year medical student at SUNY Upstate Medical University from Sacramento, CA. He obtained a B.A. from U.C. Berkeley, where he majored in Molecular and Cellular Biology. He is interested in the field of psychiatry, especially addiction medicine and novel drug therapies to treat drug dependency as well as other conditions such as depression and PTSD.

Anthony Corsi, MS3



Anthony Corsi is a third-year medical student at SUNY Upstate Medical University from Massapequa Park, NY with interests in both internal medicine and psychiatry. He received his BS in Integrative Neuroscience and Biochemistry from Binghamton University and upon graduation completed an Honors Thesis in the Department of Psychology studying the heritability of substance use in an animal model.

Jin Jin Ma, MS3, SUNY Upstate



Jin Jin Ma, a San Diego, CA native, is a third-year medical student at SUNY Upstate Medical University. He studied Neurobiology and Behavior at Cornell University before teaching 9th grade biology for a few years. Although Jin Jin is still deciding between psychiatry and surgery, he has committed to helping make healthcare more equitable. In his free time, he loves climbing rocks and dancing to great music.

Emma Brezel, MS2, AECOM



Emma Brezel, MBE is a second-year medical student at Albert Einstein College of Medicine and co-chair of the Harm Reduction and Addiction Medicine Interest Group. Before starting medical school, Ms. Brezel was a research assistant for the Montefiore-Einstein Center for Bioethics and a Project Manager for The Rose F. Kennedy Center at Montefiore-Einstein.

Kaitlyn Clausell, MS2, AECOM



Kaitlyn Clausell is also a second-year medical student at Albert Einstein College of Medicine and co-chair of the Harm Reduction and Addiction Medicine Interest Group. Kaitlyn is also co-chair for the American Geriatric Society and is interested in the intersection between addiction and neurodegeneration in the elderly.

Calla Khilnani, MS2, Icahn SOM at Mount Sinai



Calla Khilnani is currently a second-year medical student at the Icahn School of Medicine at Mount Sinai, where she is a co-leader of the Harm Reduction and Addiction Medicine Interest Group and the Nephrology Interest Group. Along with Nathaniel Saffran and Zerubabbel Asfaw, she works to train hospitalized patients who are at risk of opioid overdose on overdose response and naloxone use. Prior to medical school, she received a B.A. in Biology and Spanish from Williams College.

Nathaniel Saffran, MS2, Icahn SOM at Mount Sinai



Nathaniel Saffran is a second-year medical student at the Icahn School of Medicine at Mount Sinai and received a B.A. in Biology from Columbia University. Nathaniel is currently a leader of the Mount Sinai Harm Reduction Club and Aerospace Medicine Interest Group. He works with his exceptional peers, Calla Khilnani and Zerubabbel Asfaw, to reduce opioid overdose deaths by training at-risk patients in the use of naloxone.


Zerubabbel Asfaw, MS2, Icahn SOM at Mount Sinai



My name is Zerubabbel Asfaw. I'm a second-year medical student at the Icahn School of Medicine with a demonstrated interest in harm reduction strategies for reducing opioid-related fatal overdoses. Along with my fantastic classmates Calla Khilnani and Nathaniel Saffran, I began a medical student-led initiative to provide naloxone training and an overdose prevention kit for patients before discharge from the Mount Sinai hospital. I believe the unreserved efforts of all healthcare workers and pertinent policymakers are essential for ending the current era of addiction stigmatization and fatal overdoses. In addition to harm reduction, I'm interested in the intersection of surgery and global health. In my free time, I enjoy traveling, hiking, and water sports.

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM, Moderator (see head shot and bio in the Awards section)


Jeffrey Brent, MD, PhD



Dr. Jeffrey Brent is a Distinguished Clinical Professor of Medicine and Emergency Medicine at the University of Colorado School of Medicine and is a core faculty member of the medical toxicology fellowship program at the Rocky Mountain Poison Center. He is Principal Investigator of the Toxicology Investigators Consortium, an NIH, FDA and CDC supported multi-center research network. He is the senior editor of the text *Critical Care Toxicology: The Diagnosis and Management of Critically Poisoned Patients*, now in its second edition. Dr. Brent's primary interest is in the ICU management of critically poisoned patients.

Dr. Brent is the recipient of the ACMT's Ellenhorn Award, the AACT's Career Achievement Award, The European Association of Poisons Centres and Clinical Toxicologists' Louis Roche Award and the Society of Toxicology's Clinical and Translation Toxicology Career Achievement Award.

Barry K Logan, PhD



Dr. Barry K. Logan is Sr. V/P and Chief Scientist of Forensic Sciences at NMS Labs. He joined NMS Labs in 2008. He is also Executive Director at the non-profit Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation in Willow Grove, Pennsylvania. At NMS Labs he leads our team of forensic toxicologists and certifying scientists and is the laboratory director for NMS Criminalistics Laboratories in Pennsylvania, Texas and North Carolina.

Dr. Logan is a Fellow of the American Board of Forensic Toxicologists (ABFT), and has over 150 publications and over 600 presentations in forensic toxicology and analytical chemistry, including work on the effects of illicit and prescription drugs on drivers, and drug caused and related death. His current research priorities are focused on new drug trends, the opioid crisis, rapid reporting of drug mortality data, and the analytical and interpretive toxicology and chemistry of novel psychoactive substances, founding www.NPSDiscovery.org in 2018.

Dr. Logan's other appointments include Executive Director of the Robert F. Borkenstein course at Indiana University, and at Arcadia University and Thomas Jefferson University in Philadelphia. He serves on the Advisory Board for NIDA's National Drug Early Warning System (NDEWS). In recognition of his work and contributions, Dr. Logan has received numerous national and international awards, and served as President of the American Academy of Forensic Sciences (AAFS) in 2013-14.

Alaina Steck, MD, FASAM



Dr. Steck is an Associate Professor of Emergency Medicine at Emory University, and maintains active clinical practice in Emergency Medicine, Medical Toxicology, and Addiction Medicine at Grady Memorial Hospital in Atlanta, Georgia. She is the Medical Director of Grady's medication-assisted treatment clinic, an Assistant Medical Director at the Georgia Poison Center, and Co-Chair of the Treatment and Recovery Workgroup for the Georgia Department of Public Health's multi-stakeholder initiative to address the opioid epidemic. In addition to caring for patients at multiple stages of their substance use disorders, she is involved in research and policy development to optimize pain management and substance use treatment outcomes. She is engaged in several initiatives in an advisory capacity, including a novel emergency department-based post-overdose program, a warm handoff program to ensure linkage to care for patients being discharged from the hospital, and educational programs for undergraduate and graduate medical trainees.

Paul Wax, MD, FACMT



Dr. Wax is the Executive Director of the American College of Medical Toxicology. Dr. Wax received his B.A from Dartmouth College, his M.D. from the Mount Sinai School of Medicine, his Emergency Medicine training Draft University. He is Board-certified in both Medical Toxicology and Emergency Medicine and is a Fellow of the American College of Medical Toxicology.

Before joining ACMT in 2008 as its Executive Director, Dr. Wax had faculty appointments in the Departments of Emergency Medicine at the University of Rochester School of Medicine from 1991-2001 and the University of Arizona School of Medicine from 2001-2006. Since 2006 Dr. Wax has served as part-time faculty at UT Southwestern Medical School in Dallas, TX. In 2019 Dr. Wax received the Mathew J Ellenhorn Career Achievement Award in Medical Toxicology from the American College of Medical Toxicology.

In 2010 Dr Wax co-founded ACMT's Toxicology Investigators Consortium, known as ToxIC. A multicenter research consortium and patient registry, ToxIC currently receives federal funding from CDC, NIH, and FDA.

Thank you to our generous sponsors!



ASAM American Society of
Addiction Medicine

ABOUT US /

Founded in 1954, ASAM is a professional society representing more than 3,800 physicians, clinicians and associated professionals in the field of addiction medicine.

GOAL /

ASAM is dedicated to increasing access to and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addiction.

MISSION /

Increase access to and improve the quality of addiction treatment;

Educate physicians (including medical and osteopathic students), other health care providers and the public;

Support research and prevention;

Promote the appropriate role of the physician in the care of patients with addiction;

Establish addiction medicine as a specialty recognized by professional organizations, governments, physicians, purchasers and consumers of health care services, and the general public.



NEW YORK STATE DEPARTMENT
OF HEALTH AIDS INSTITUTE

CLINICAL INQUIRY FOR: HIV | HCV | DUH | STI | PEP | PREP

The Clinical Education Initiative (CEI) is a New York State Department of Health AIDS Institute program designed to enhance the capacity of New York’s diverse workforce to deliver clinical services that improve health outcomes related to HIV, Sexual Health, Hepatitis C and Drug User Health. Our aims are fourfold:

1. Educate clinicians by providing free continuous and innovative drug user health, HIV, pre- and post-exposure prophylaxis (PEP/PrEP), hepatitis C and sexual health trainings, webinars and conferences.
2. Expand the base of New York providers able to diagnose and care for patients impacted by drug use, hepatitis C, HIV and sexually transmitted infections.
3. Disseminate AIDS Institute clinical practice guidelines, relevant materials and resources.
4. Foster partnerships among community-based providers, affiliated organizations and drug user health, hepatitis C, HIV and sexual health specialists.

CEI’s Hepatitis C and Drug User Health Center of Excellence provides trainings with free continuing medical education credit, intensive preceptorship programs, tele-mentoring through our Drug User Health ECHO™ and HepCure, technical assistance, free clinical cards for buprenorphine and harm reduction, the “Conversations with CEI” podcast and additional clinical tools. Our CEI Line is a toll-free number for clinicians in New York State to discuss drug user health, hepatitis C, HIV, PEP, PrEP and sexual health patient management with a technical expert.

hikma.

Addiction Therapy Services

Hikma Pharmaceuticals USA Inc. is a recognized leader for the research, development, sales, and marketing of multisource pharmaceutical products. Specific to Addiction Treatment, Hikma Pharmaceuticals offers the following products; Methadone HCl Oral Concentrate, Methadone 40mg Diskets® Dispersible Tablets, Methadone 5mg and 10mg Tablets, Buprenorphine HCl Sublingual Tablets, Buprenorphine HCl and Naloxone Sublingual Tablets, and Buprenorphine and Naloxone Sublingual Film. In addition, Hikma is now excited to offer Kloxxado, an 8mg Naloxone Nasal Spray.

For additional product information, including the Full Prescribing Information with complete indications for use, warnings, precautions and adverse reactions for each product, please visit hikma.com.



Addiction Therapy Services

Toll Free 1.833.449.3475

Fax: 1.866.464.1562


Email: usaddictiontherapy@hikma.com

hikma.

©2021 Hikma Pharmaceuticals USA Inc. All rights reserved. 200 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922



Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide.



**Together, we
can tackle the
opioid addiction
crisis and
other mental
health disorders.**

Opioid addiction and mental health disorders can make individuals feel isolated and alone. Opioid Use Disorder is increasingly recognized as a treatable medical disease. Medications and treatments are available to help patients and caregivers manage OUD and mental health disorders.

Through education, advocacy, policy, access, resources, treatment, and innovation, Indivior can help.

www.rethinkopioidaddiction.com



INDIVIOR[®]
Focus on you.

© Indivior PLC | INDIVIOR is a registered trademark of Indivior UK Limited
NP-NBD-US-00474 | 03/19/2021 | August 2021 | All rights reserved



Helio Health is a comprehensive, evidence-based and clinically progressive substance use disorders and mental health disorders services provider. Helio Health operates in Syracuse, Rochester, Binghamton, and Utica New York. Services include: **Inpatient Withdrawal and Stabilization; Inpatient Rehabilitation; Outpatient Substance Use Disorders Clinic; Outpatient Mental Health Clinic; Outpatient Compulsive Gambling Clinic; Day-Rehabilitation; Outpatient Child & Adolescent Clinic; School Based-Services; Opioid Treatment Programs; Mobile Health Outreach; Certified Community Behavioral Health Clinic; Residential Stabilization, Rehabilitation, and Reintegration; Community Residences; Supportive Living; Permanent Housing; Affordable Housing; Recovery Services; Behavioral Healthcare Training Institute; Peer Support and Engagement; 24/7 Regional Open Access Center for Addiction.** Helio Health's mission is to promote recovery from the effects of substance use and mental health disorders and other health issues.



Addiction and mental illness can affect anyone.

Recovery takes everyone.

Helio Health is dedicated to transforming the lives of those struggling with substance use and mental health disorders. Providing hope and healing with an array of comprehensive, innovative, and compassionate residential, housing, treatment, and in-community supports. Our programs in Binghamton, Rochester, Syracuse, and Utica assist individuals on their recovery journey.



Helio Health[®]
Where hope meets healing
www.helio.health





Truetox Laboratories, LLC located in Garden City Park, NY provides a wide range of toxicology services in both urine and saliva (medication monitoring and drug detection services) Our medical professional services are provided to physician offices, opiate treatment programs, drug free facilities, behavioral health programs and drug court. We pride ourselves on not being a “big box” toxicology laboratory because it gives us a competitive edge. This business model allows us the ability to be nimble and adaptable to change. It also gives us an opportunity to provide a better customer experience while providing some of the most cutting-edge technology in the industry. Come visit us during breakout to learn more about how Truetox, and Hometox can benefit your practice today.

The advertisement features a central image of a person's hands holding a smartphone. The screen shows a smiling woman on a video call. To the right of the phone, white text on a dark background reads: "Enhance your teletherapy session with HomeTox,™ an oral fluid testing solution." Below this text is the HomeTox logo, which consists of a green house icon with a white test tube inside, followed by the word "HOMETOX" in a bold, blue, sans-serif font. Underneath "HOMETOX" is the tagline "A TRUETOX LABORATORIES RESOURCE" in a smaller, blue, sans-serif font.

**Truetox's Enhanced SALIVA Tests Feature
The Most Advanced Testing Options.**